Published in final edited form as:

J Med Chem. 2010 July 22; 53(14): 5290–5301. doi:10.1021/jm1004978.

Analogues of (3*R*)-7-Hydroxy-*N*-[(1*S*)-1-[(3*R*,4*R*)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidiny]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and In Vitro and In Vivo Opioid Receptor Antagonist Activity

Scott P. Runyon[†], Lawrence E. Brieady[†], S. Wayne Mascarella[†], James B. Thomas[†], Hernán A. Navarro[†], James L. Howard[‡], Gerald T. Pollard[‡], and F. Ivy Carroll^{*,†}

[†]Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, North Carolina 27709

[‡]Howard, LLC, Research Triangle Park, North Carolina 27709

Abstract

The synthesis of compounds **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** where the amino -NH- group of JDTic (**3**) was replaced with an aromatic =CH-, CH₂, O, S, or SO group was accomplished and used to further characterize the SAR of the compound **3** class of κ opioid receptor antagonists. All of the compounds showed subnanomolar to low nanomolar K_e values at the κ opioid receptor. The most potent compound was **7a**, where the amino -NH- group of **3** was replaced by a methylene (-CH₂-) group. This compound had a K_e = 0.18 nM and was 37- and 248-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Similar to compound **3**, compound **7a** antagonized selective κ agonist U50,488-induced diuresis after s.c. administration in rats. In contrast to **3**, where κ antagonist activity lasted for three weeks, compound **7a** did not show any κ antagonist activity after one week.

Introduction

Kappa opioid receptor selective antagonists are of considerable interest as potential pharmacotherapies for addiction (cocaine, opiate, alcohol, nicotine, and possibly others),¹⁻⁷ depression,^{1,8-10} anxiety disorders,¹¹ obesity,¹²⁻¹⁴ and psychosis disorders.¹⁵ Opioid antagonists with varying degrees of receptor potency and selectivity have been developed for the κ opioid receptor. The first highly selective and potent κ opioid receptor antagonist was norBNI (**1**).^{16,17} Continued studies identified 5'-GNTI (**2**) as a more potent and selective κ opioid antagonist.¹⁸⁻²⁰ In 2001, JDTic (**3**), an *N*-substituted *trans*-(3*R*,4*R*)-dimethyl-4-(3-hydroxyphenyl)piperidine analog, was developed as the first highly potent and selective κ opioid receptor antagonist from this class of opioid antagonists.²¹ More recently, the dynorphin analogues zyklophin and arodyn (**4** and **5**, respectively) were developed as selective κ opioid receptor antagonists.^{22,23}

SAR studies previously conducted on **3** identified the 7'-phenolic and (*S*)-2'-isopropyl groups as features important for the κ selectivity and suggested that the nitrogen of the

* To whom correspondence should be addressed. Telephone: 919-541-6679. Fax: 919-541-8868. fic@rgi.org.

Supporting Information Available: Elemental analysis data for compounds **6**, **7a,b**, **9a,b**, and **10a,b** and HPLC traces for **8a** and **8b**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

hydroxy-D-Tic group might also be uniquely required for the κ selectivity.²⁴⁻²⁶ To gain additional information as to the role that the amine nitrogen of the hydroxy-D-Tic group plays in determining the κ opioid in vitro antagonist efficacy and selectivity, the JDTic analogues **6**, **7a,b**, and **8a,b**, **9a,b**, and **10a,b**, where the amino -NH- group was replaced with an aromatic =CH-, CH₂, O, S, or SO group, were synthesized and evaluated for their ability to antagonize μ , δ , and κ opioid agonists in a [³⁵S]GTP γ S in vitro antagonist efficacy test. The stereochemical assignments for the position alpha to the carbonyl group for compounds **7a,b**, **8a,b**, and **9a,b** are arbitrary. The isomer with the lowest K_e value for the κ opioid receptor in each pair was given the **a** designation. Compounds **10a,b** are the two possible sulfoxide diastereoisomers derived from **9a**.

Analogue **7a**, with a K_e = 0.18 nM at the κ opioid receptor and 37- and 248-fold selectivity for the κ receptor relative to the μ and δ opioid receptors, was the most potent and selective analogue tested. The potency and duration of action of **7a** to antagonize κ agonist U50,488-induced diuresis in rats was compared to that of **3**.

Chemistry

Analogues **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** of **3** were synthesized by the methods depicted in Schemes 1–3. Coupling of 6-hydroxy-2-naphthoic acid (**11**) with 3-{1-[(2*S*)-amino-3-methylbutyl]-(3*R*,4*R*)-dimethyl-4-piperidinyl}phenol (**12**)²⁷ using benzotriazole-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) in tetrahydrofuran containing triethylamine at 25 °C gave the desired analogue **6** (Scheme 1). Our initial plan for the synthesis of **7a** and **7b** was to start with (+)- and (-)-**13**. Since all attempts to resolve (±)-**13** directly into its optical isomers were unsuccessful, we used the strategy outlined in Scheme 2 to prepare (+)- and (-)-**13**, which were then converted to **7a** and **7b**. This strategy was based on a report from Fox et al.²⁸ who showed that the tetrahydro-2*H*-indeno[1,2*d*]-2-ones serve as a readily cleavable chiral auxiliary suitable for large-scale normal phase separation of isomers. Thus, treatment of (3*aR*-*cis*)-3,3*a*,8,8*a*-tetrahydro-2*H*-indeno[1,2*d*]oxazol-2-one (**14**) with ethyl lithium provided the lithium salt, which was acetylated with the acid chloride prepared by treating (±)-**13**²⁹ with thionyl chloride in toluene, to give **15a** and **15b**, which were separated by standard silica chromatography. Hydrolysis of **15b** using lithium hydroxide in tetrahydrofuran containing 30% hydrogen peroxide yielded (+)-**13**.³⁰ Coupling of (+)-**13** to **12**²⁷ using BOP in tetrahydrofuran containing triethylamine at 25 °C provided **16a**. Treatment of **16a** with boron tribromide in methylene chloride at -78 °C afforded **7a**. Subjecting **15a** to the same set of reaction conditions provided (-)-**13**, **15b**, and **7b**.

Based on the ease of separating **7a,b** using chiral auxiliary **14**, a similar synthetic strategy was applied to the synthesis of **9a,b** and **10a,b**. In this case, the synthesis of the 7-methoxy-isothiochroman-3-carboxylic acid [(±)-**20**] had to be developed. Scheme 3 outlines the synthesis used to prepare (+)- and (-)-**20** and subsequent conversion to **9a** and **9b**. Condensation of 7-methoxy-isothiochroman-4-one (**17**)³¹ with methyl cyanofornate using lithium diisopropylamide (LDA) as the base in tetrahydrofuran containing hexamethylphosphoramide (HMPA), gives keto ester (**18**).³² Reduction of **18** using triethylsilane in trifluoroacetic acid effected removal of the 4-keto group to give **19**.³³ Hydrolysis of **19** using potassium hydroxide in methanol provided (±)-**20**. The lithium salt of **14** was acylated with the acid chloride prepared by treating (±)-**20** with oxalyl chloride in methylene chloride to give **21a** and **21b**, which were separated by normal phase silica gel chromatography. Hydrolysis of **21a** using lithium hydroxide in aqueous tetrahydrofuran afforded (+)-**20**. It should be noted that hydrolysis of the auxiliary was equally effective without the presence of peroxide in the basic media. Coupling of (+)-**20** with **12**²⁷ using BOP in tetrahydrofuran containing triethylamine at 25 °C provided **22a**. Treatment of **22a** with boron tribromide in methylene chloride at -78 °C afforded **9a**. Subjecting **21b** to a set

of reaction conditions analogous to those used for **21a** provided (-)-**20**, **22b**, and **9b**. Oxidation of **9a** using 3-chloroperoxybenzoic acid in methylene chloride provided sulfoxide diastereomers **10a** and **10b** that were separated using normal phase silica gel chromatography.

The synthesis of compounds **8a** and **8b** was more complex than that of **7a,b** and **9a,b** due to the requirement of phenolic protecting groups in the presence of a benzylic ether (see Scheme 4). Cyclization of 3-methoxybenzyloxyacetic acid (**23**) using oxalyl chloride followed by tin IV chloride in chlorobenzene yielded chromanone **24**.³⁴ Demethylation of **24** to the phenol **25** was accomplished using sodium ethanethiolate in dimethylformamide.³⁵ The phenol group in **25** was reprotected as the methoxymethyl ether **26** using chloromethylmethyl ether and diisopropylethylamine in methylene chloride. Condensation of **26** with methyl cyanoformate using lithium diisopropylethylamine as the base in tetrahydrofuran containing hexamethylphosphoramide (HMPA) afforded the keto ester **27**.³² Treatment of **27** with triethylsilane in trifluoroacetic acid afforded both removal of the 4-keto group, and the methoxymethyl protecting group to give **28**.³³ Hydrolysis of **28** using lithium hydroxide in water, tetrahydrofuran, ethanol mixture provided (±)-**29**. Coupling of (±)-**29** to **12** using BOP in tetrahydrofuran containing triethylamine at 25 °C yielded a mixture of (+)-**8** that were separated using reverse phase HPLC to provide **8a,b**.

Pharmacology

Compounds **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** were first evaluated at 10 μM for intrinsic activity in the [³⁵S]GTPγS binding assay at all three opioid receptors. As none of these compounds displayed measurable intrinsic activity at this concentration, they and the reference compound **1** were evaluated for antagonist efficacy and selectivity at the opioid receptors. These data were obtained by monitoring the ability of test compounds to inhibit stimulated [³⁵S]GTPγS binding produced by the selective agonists DAMGO (μ), DPDPE (δ), or U69,593 (κ) using cloned human opioid receptors expressed in CHO cells.³⁶ Agonist dose response curves were run in the presence or absence of a single concentration of test compound. The K_e values were calculated using the formula: K_e = [L]/DR-1, where [L] is the concentration of test compound and DR is the ratio of agonist EC₅₀ value in the presence or absence of test compound, respectively. At least two different concentrations of test compound were used to calculate the K_e, and the concentrations were chosen such that the agonist EC₅₀ exhibited at least a four-fold shift to the right and there was a clear upper asymptote to the agonist + compound concentration response curve. The K_e values along with those for the reference compound **1** are shown in Table 1.

Compound **7a** was evaluated for its ability to antagonize U50,488-induced diuresis in male Sprague-Dawley rats (Charles River Laboratories, Raleigh, NC).

Results and Discussion

Compounds **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** were evaluated for their μ, δ and κ agonist or antagonist activity in the [³⁵S]GTPγS antagonist efficacy binding assay. The data are shown in Table 1 compared to **1** and **3**. None of the compounds had any μ, δ, or κ intrinsic activity at 10 μM. As expected, all compounds were antagonists of the DAMGO (μ), DPDPE (δ), or U69,593 (κ) stimulated binding. Similar to **1** and **3**, the compounds were more potent at the μ and κ than at the δ opioid receptor. Compounds **1** and **3** with K_e values of 0.05 and 0.02 nM, respectively, are highly potent antagonists for the κ receptor. In addition, both compounds are highly selective for the κ relative to the μ and δ opioid receptors. The compounds **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** where the amino -NH- groups have been replaced by an aromatic =CH-, -CH₂-, O, S, or SO group, showed K_e values ranging from 0.18 to 5.7

nM for κ , 1.8 to 13.4 nM for μ , and 44.8 to 395 nM for δ , and thus are potent κ and μ opioid receptor antagonists. In the cases of **7**, **8**, **9**, and **10**, one isomer was more potent than the other isomer. The differences in potencies were 7.6-, 8-, 1.6-, and 4.9-fold for **7a,b**, **8a,b**, **9a,b**, and **10a,b**, respectively. The K_e values at the κ opioid receptor for the more potent **7a**, **8a**, and **9a** are 0.18, 0.77, and 0.99 nM, respectively. The diastereomeric sulfoxides **10a** and **10b** prepared from **9a** had K_e values of 2.7 and 0.55 nM at the κ opioid receptor, respectively. The more potent isomers **7a**, **8a**, **9a**, and **10b** are 9-, 36-, 50-, and 28-times less potent than **3** as a κ opioid antagonist. This data shows that replacing the amino -NH- group of **3** with a -CH₂- was better tolerated at the κ opioid receptor than replacement by an -O- or -S-. Compound **7a** with K_e values of 6.67, 44.8, and 0.18 nM at the μ , δ , and κ opioid receptors was the most potent and selective κ opioid receptor antagonist of the compounds evaluated. The low antagonist efficacy of compounds **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** relative to **3** strongly suggests that the -NH group of **3** is critical to its high in vitro antagonist efficacy at the κ opioid receptor.

With the exception of **8b**, all of the compounds were less potent at the μ opioid receptor than the κ opioid receptor. However, with the exception of **7a**, which had a 37-fold selectivity for κ over μ , the potencies of the μ and κ opioid receptor were similar. The K_e values at the μ opioid receptor ranged from 1.8 to 11.2 nM. The sulfoxide **10b** with a K_e = 1.8 nM was the most potent μ opioid antagonist. All of the compounds had relative low antagonist efficacies for the δ opioid receptor. Compound **7a** with a K_e = 44.8 shows the highest potency at the δ opioid receptor.

Structure activity relationship (SAR) studies of **1** and **2** and analogues led Portoghesi to propose that the 17'-amino group of **1** and the 5'-guanidiny amino moiety of **2** as the primary structural features leading to the κ opioid selectivity of these two compounds (see Metcalf and Coop³⁷ and Aldrich³⁸ for reviews of the SAR studies). Portoghesi and co-workers explained the κ selectivity of **1** and **2** using the message-address concept developed by Schwyzler³⁹ for peptide hormones. In this concept, molecular features common to a series of compounds recognized by a family of receptors are defined as the message. The "address" portion of this concept is a specific structural feature of the ligand that affords sub-type selectivity through interaction with a site or specific residue(s) unique to a receptor subtype. In the case of **1** and **2**, Portoghesi used molecular modeling studies⁴⁰ coupled with site-directed mutagenesis to provide additional evidence that the 17'-amino group of **1** and the 5'-guanidinium amino group of **2** serve as the address by forming an ion pair with Glu297 at the top of the TM6 in the κ opioid receptor.^{19,41-44}

In order to determine if **3** could be interacting with the κ opioid in a way similar to that proposed for **2** and **1**, structures of **3** and **2** were constructed and compared. Low-energy conformations of **3** which provide an overlay of the primary pharmacophoric groups of **3** and **2** (as represented by the centroid of the phenolic rings of **3** and **2** and the centroid of the Tic aromatic ring of **3** and the guanidinium group of **2**) were identified via conformational analysis (Figure 1). Although the geometry and dimensions of **3** conformations do not permit an atom-for-atom overlay of the 7-hydroxy-D-Tic-group hydrogen-bonding substituents of **3** with the guanidinium nitrogens of **2**, both the 7-hydroxy-D-Tic secondary amine NH group and phenol oxygen are projected into the same general region and presumably could participate in some type of interactions in the κ -address locus proposed for **1** and **2** of the κ -opioid receptor (Figure 1).

Compounds **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** all have a phenol group in a location similar to the 7-hydroxy-D-Tic phenol group of **3** but lack the -NH group present in **3**. Therefore, the lower κ opioid antagonist efficacy of each to these compounds seems due largely to the absence of the -NH group present in **3**. Previous studies have shown that the 7-hydroxy-D-

Tic phenol oxygen is essential for the high κ opioid receptor efficacy of **3**.^{25,26} Thus, these results suggest that the highly potent κ opioid receptor efficacy of **3** is due to strong interactions at the κ opioid receptor by the 7-hydroxy-D-Tic secondary amine -NH group and the phenol oxygen as suggested by the molecular modeling studies (Figure 1). However, these results do not rule out the possibility that **3** is interacting with the κ opioid receptor in a way different from that of **1** and **2**.

In order to gain information concerning the in vivo activity, the effect of **7a** to antagonize κ agonist U50,488-induced diuresis was compared to that of **3**. The results from the study are summarized in Figure 2. At week 0 (first 5 h after dosing s.c.), compound **3** showed dose-related antagonism of urine output relative to vehicle (Figure 2A). At week 1 (no further dosing with **3**), **3** continued to show dose-related antagonism of U50,488-induced diuresis. In keeping with our previous findings with **3**,⁴⁵ the level of antagonism at week 1 was the same as or greater than at week 0.

At week 0 (first 5 h after dosing s.c.), **7a** showed dose-related antagonism of U50,488-induced diuresis but was less potent than **3**, which is consistent with its nine-fold lower in vitro antagonist potency at the κ opioid receptor compared to **3** in the [³⁵S]GTP γ S in vitro antagonist efficacy test (Figure 2B). Repeated measures ANOVA (StatView v5; SAS Institute Inc., Cary, NC) with factors of Dose and Week revealed a marginally significant effect of Dose ($F_{(3,12)} = 2.74$; $P < 0.1$) but a significant Dose $\times$ Week interaction ($F_{(1,12)} = 106.8$; $P < 0.0001$). Examining the data within week indicated the ability of **7a** to antagonize U50,488-mediated diuresis was dose dependent and confined to week 0. The effect of individual doses of **7a** on urine output was compared to U50,488 using Dunnett's test. At week 0, ANOVA indicated there was a significant overall effect of Dose ($F_{(3,12)} = 7.53$; $P < 0.005$) to lower urine output, with the 10 and 30 mg/kg doses causing significant antagonism of the diuretic effects of U50,488. However, at week 1 (no further dosing with **7a**), antagonism of U50,488 could no longer be detected (ANOVA; $F_{(1,12)} = 0.69$; NS). Thus, the activity of **7a** lasted less than 1 week, which contrasts sharply with the activity of **3** as well as other κ opioid receptor antagonists such as **1**, which can persist for up to 3 weeks.⁴⁵ The shorter duration of action of **7a** compared to **3** and **1** showed that selective, high affinity κ opioid receptor antagonists can be identified with shorter durations of activity.

In summary, replacement of the amino -NH- group of **3** with an aromatic =CH-, -CH₂-, O, or S provided compounds with reduced κ opioid receptor in vitro antagonist potency and reduced κ selectivity relative to the μ and δ opioid receptors. These results confirm our earlier results showing that the amino -NH- group of **3** is highly important to its high κ opioid receptor in vitro antagonist potency as well as κ selectivity. However, molecular modeling studies show that the amino -NH- group of **3** and the amino group in GNTI are not likely to be interacting with the κ opioid receptor in the same way. Interestingly, compound **7a**, where the amino -NH- of **3** has been replaced by a methylene (-CH₂-) group, showed subnanomolar κ potency and reasonable selectivity for the κ relative to the μ and δ opioid receptors. Compound **7a** antagonized selective κ agonist U50,488-induced diuresis with a potency that parallels its κ efficacy in the [³⁵S]GTP γ S antagonist assay. In contrast to **3**, whose activity as an antagonist of U50,488-induced diuresis lasted for 3 weeks, the activity of **7a** lasted less than 1 week.

Experimental Section

¹H NMR spectra were determined on a Bruker 300 spectrometer using tetramethylsilane as an internal standard. Mass spectral data were obtained using a Finnegan LCQ electrospray mass spectrometer in positive ion mode at atmospheric pressure. Silica gel 60 (230–400 mesh) was used for column chromatography. All reactions were followed by thin-layer

chromatography using Whatman silica gel 60 TLC plates and were visualized by UV. Optical rotations were measured on an Auto Pol III polarimeter. All solvents were reagent grade. HCl in dry diethyl ether was purchased from Aldrich Chemical Co. and used while fresh before discoloration. CMA-80 is a mixture of 80% chloroform, 18% methanol, and 2% concentrated ammonium hydroxide. MMA-80 is a mixture of 80% methylene chloride, 18% methanol, and 2% concentrated ammonium hydroxide. Purity of compounds (>95%) was established by elemental analysis except for **8a** and **8b**. HPLC analysis was used to establish their purity. Elemental analysis was performed by Atlantic Microlab, Inc., Norcross, GA, USA.

HPLC-grade solvents were purchased from Burdick & Jackson (Muskegon, MI, USA). Preparative HPLC was carried out utilizing a Varian Prostar HPLC system (Walnut Creek, CA, USA) equipped with Prostar 210 pumps, Prostar 701 fraction collector, and a Prostar 335 photodiode array detector (PDA), with data collected and analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2). Analytical HPLC was carried out utilizing a Varian Prostar HPLC system (Walnut Creek, CA, USA) equipped with Prostar 210 pumps and a Prostar 330 photodiode array detector (PDA), with data collected and analyzed using Star Chromatography Workstation software (version 6.41). For preparative HPLC, a Gemini-NX C18 (5 μ M; 250 $\times$ 21.2 mm) column was used with a 19 mL/min flow rate, while for analytical HPLC, a Gemini-NX C18 (5 μ m; 250 $\times$ 4.6 mm) column was used with a 1 mL/min flow rate (both from Phenomenex, Torrance, CA, USA). For analytical HPLC, a MetaTherm HPLC column temperature controller (Varian) maintained the column at 30 $^{\circ}$ C.

6-Hydroxynaphthalene-2-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide Hydrochloride (6**)**

6-Hydroxy-2-naphthoic acid (100 mg, 0.53 mmol) was added to a solution of **12**²⁷ (154 mg, 0.53 mmol) and BOP reagent (235 mg, 0.53 mmol) in THF (40 mL) and was allowed to stir under nitrogen for 15 min. Triethylamine (1.18 g, 0.012 mol) in THF (10 mL) was added, and the reaction mixture was allowed to stir at room temperature for 3 h. NaHCO₃ (50 mL) and Et₂O (50 mL) were added to the reaction mixture, and the organic layer was separated, washed with brine, dried, (Na₂SO₄), and concentrated under reduced pressure to afford 0.32 g of an amorphous solid. The solid was purified using medium pressure silica gel chromatography, eluting with EtOAc–CMA80 (1:1) to afford 0.095 g of a white amorphous solid. ¹H NMR (CDCl₃) δ 8.20 (s, 1H), 7.75 (m, 2H), 7.62 (d, *J* = 9.0 Hz, 1H), 7.10 (m, 4H), 6.71 (m, 2H), 6.60 (d, 6.0 Hz, 1H), 4.42 (m, 1H), 2.32–2.92 (bm, 7H), 2.25 (bt, 1H), 2.05 (m, 1H), 1.92 (bs, 1H), 1.57 (bd, 1H), 1.27 (s, 3H), 1.06 (dd, *J* = 4.8, 2.1 Hz, 6H), 0.55 (d, *J* = 6.9 Hz, 3H). The resulting solid was dissolved in CH₂Cl₂–MeOH (1:1) and acidified with 1M ethereal HCl. The mixture was concentrated in vacuo, then dried to yield 0.065 g (23%) of **6** as a white solid: mp 207–211 $^{\circ}$ C. Anal. (C₂₉H₃₇ClN₂O₃•2 H₂O) C, H, N.

6-Hydroxy-1,2,3,4-tetrahydro-naphthalene-2(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (7a**) Hydrochloride**

A 1.0 M solution of BBr₃ (8.2 mL, 8.2 mmol) in CH₂Cl₂ was added at -78 $^{\circ}$ C under N₂ to **16b** (0.39 g, 0.82 mmol) in CH₂Cl₂ (25 mL). The dark brown solution was allowed to stir at -78 $^{\circ}$ C for 0.5 h and allowed to warm to room temperature. A saturated solution of NaHCO₃ (50 mL) was cautiously added, and the biphasic mixture was extracted with EtOAc (3 $\times$ 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a brown oil. The oil was purified using medium pressure column chromatography on silica using CHCl₃–MeOH–NH₄OH (8:1.8:0.2) as the eluent to provide 0.30 g (77%) of **7a** as a colorless oil. The hydrochloride salt was prepared by adding a 1.0 M solution of HCl in Et₂O to the free base in MeOH. The solution was concentrated under

reduced pressure and the resulting solid recrystallized from EtOH–Et₂O to provide **7a**•HCl as white plates: mp 189–191 °C; [α]_D²² +113.7 °C (c = 0.18, MeOH). ¹H NMR (CD₃OH) δ 0.74 (d, *J* = 6.78 Hz, 3 H), 0.90 (d, *J* = 6.78 Hz, 3 H), 0.93 (d, *J* = 6.78 Hz, 3 H), 1.27 (s, 3 H), 1.55 (d, *J* = 12.81 Hz, 1 H), 1.68–1.89 (m, 2 H), 1.95 (m, 2 H), 2.36–2.81 (m, 12H), 4.02 (ddd, *J* = 9.61, 5.09, 4.90 Hz, 1 H), 6.50 (d, *J* = 2.26 Hz, 1 H), 6.57 (ddd, *J* = 15.26, 8.10, 2.26 Hz, 2 H), 6.70–6.80 (m, 2 H), 6.85 (d, *J* = 8.29 Hz, 1 H), 7.10 (t, *J* = 8.10 Hz, 1 H), 7.81 (br s, 1 H). Anal. (C₂₉H₄₁ClN₂O₃•0.75 H₂O) C, H, N.

6-Hydroxy-1,2,3,4-tetrahydro-naphthalene-2(-)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (7b**) Hydrochloride**

A 1.0 M solution of BBr₃ (8.2 mL, 8.2 mmol) in CH₂Cl₂ was added at -78 °C under N₂ to **16a** (0.70 g, 1.45 mmol) in CH₂Cl₂ (50 mL). The dark brown solution was allowed to stir at -78 °C for 0.5 h and allowed to warm to room temperature. A saturated solution of NaHCO₃ (100 mL) was cautiously added, and the biphasic mixture was extracted with EtOAc (3 × 150 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a brown oil. The oil was purified using medium pressure column chromatography on using silica CHCl₃–MeOH–NH₄OH (8:1.8:0.2) as the eluent to provide 0.057 g (83%) of **7b** as a colorless oil. The hydrochloride salt was prepared by adding a 1.0 M solution of HCl in Et₂O to **7b** in MeOH. The solution was concentrated under reduced pressure and recrystallized from EtOH–Et₂O to provide **7b**•HCl as tan cubes: mp 193–195 °C; [α]_D²² + 67.0 °C (c = 0.22, MeOH). ¹H NMR (CD₃OD) δ 0.76 (d, *J* = 7.32 Hz, 3 H), 0.91 (d, *J* = 6.84 Hz, 3 H), 0.95 (d, *J* = 6.84 Hz, 3 H), 1.27–1.30 (s, 3 H), 1.57 (d, *J* = 11.23 Hz, 1 H), 1.75–1.86 (m, 2 H), 1.95–2.03 (m, 2 H), 2.29 (td, *J* = 12.57, 4.15 Hz, 1 H), 2.34–2.41 (m, 1 H), 2.42–2.87 (m, 10 H), 4.02 (dt, *J* = 9.77, 4.88 Hz, 1 H), 6.49 (m, 1 H), 6.52 (dd, *J* = 8.30, 2.44 Hz, 1 H), 6.58 (dd, *J* = 7.81, 1.95 Hz, 1 H), 6.74 (m, 1 H), 6.77 (d, *J* = 7.81 Hz, 1 H), 6.82 (d, *J* = 8.30 Hz, 1 H), 7.10 (t, *J* = 8.06 Hz, 1H). Anal. (C₂₉H₄₁ClN₂O₃•1.5 H₂O) C, H, N.

7-Hydroxy-3,4-dihydro-1*H*-isochromene-3-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (8a,b**)**

7-Hydroxy-3,4-dihydro-1*H*-isochromene-3-carboxylic acid [(±)-**29**, 66 mg, 0.34 mmol] was added to a solution of **12**²⁷ (98 mg, 0.34 mmol) and BOP reagent (150 mg, 0.34 mmol) in THF (20 mL) and was allowed to stir under nitrogen for 15 min. Triethylamine (69 mg, 0.68 mmol) in THF (10 mL) was added, and the reaction was allowed to stir at room temperature for 3 h. To the reaction mixture were added NaHCO₃ (30 mL) and Et₂O (30 mL), and the organic layer was separated, washed with brine, dried, (Na₂SO₄), and concentrated under reduced pressure to afford an oil. The oil was purified by medium pressure silica gel chromatography, eluting with CHCl₃–CMA80 (1:1) to afford 0.129 g of a pale yellow oil as a mixture of **8a** and **8b**. The diastereomers were purified using preparative HPLC. A sample of 41 mg of **8a,b** in DMSO (200 μ L) was purified via reversed phase HPLC using an isocratic MeOH–H₂O (0.1% DEA) solvent system at 19 mL/min for 35 min, and 19-mL fractions were collected. Fractions were combined to obtain two pools. The first pool contained 21.6 mg of 100% pure compound **8a** (the first compound to elute), and the second pool contained 16 mg of **8b**, the second peak determined to be 87% pure. The second peak was repurified to afford 9.2 mg of **8b** at 98.7% purity. The purity of isolates was determined via analytical HPLC using an isocratic solvent system at MeOH–H₂O (70:30) (0.1% DEA) for 15 min. Chromatograms were observed at 220 nm, and the samples were dissolved in MeOH.

7-Hydroxy-3,4-dihydro-1*H*-isochromene-3-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (8a, peak 1)

$[\alpha]_D^{22} +108.6$ °C, (c 0.11, MeOH). ^1H NMR (CDCl_3) δ 0.71 (d, $J = 6\text{ Hz}$, 3H), 0.93 (m, 6H), 1.28 (m, 4H), 1.56 (d, $J = 12\text{ Hz}$, 1H), 1.87 (m, 1H), 1.95 (m, 1H), 2.26 (ddd, 1H), 2.41–2.55 (m, 4H), 2.64–2.80 (m, 2H), 2.90–2.96 (dd, $J = 3, 18\text{ Hz}$, 1H), 3.99 (m, 1H), 4.14 (dd, $J = 6, 12\text{ Hz}$, 1H), 4.84 (d, 1H), 4.87 (d, $J = 12\text{ Hz}$, 1H), 6.45 (s, 1H), 6.58 (m, 2H), 6.71 (m, 2H), 6.91 (d, $J = 9\text{ Hz}$, 1H), 7.07 (dd, $J = 9, 9\text{ Hz}$, 1H). HRMS m/z 467.2908 ($\text{M}+\text{H}$) $^+$, predicted 467.2910.

7-Hydroxy-3,4-dihydro-1*H*-isochromene-3-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (8b, peak 2)

$[\alpha]_D^{22} -16.3$ °C (c 0.08, MeOH). ^1H NMR (CDCl_3) δ 0.71 (d, $J = 6\text{ Hz}$, 3H), 0.93 (m, 6H), 1.28 (m, 4H), 1.56 (d, $J = 12\text{ Hz}$, 1H), 1.87 (m, 1H), 1.95 (m, 1H), 2.26 (ddd, 1H), 2.41–2.55 (m, 4H), 2.64–2.80 (m, 2H), 2.90–2.96 (dd, $J = 3, 18\text{ Hz}$, 1H), 3.99 (m, 1H), 4.14 (dd, $J = 6, 12\text{ Hz}$, 1H), 4.84 (d, 1H), 4.87 (d, $J = 12\text{ Hz}$, 1H), 6.45 (s, 1H), 6.58 (m, 2H), 6.71 (m, 2H), 6.91 (d, $J = 9\text{ Hz}$, 1H), 7.07 (dd, $J = 9, 9\text{ Hz}$, 1H). HRMS m/z 467.2905 ($\text{M}+\text{H}$) $^+$, predicted 467.2910.

7-Hydroxyisothiochroman-3(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (9a)

A 1.0 M solution of BBr_3 (9.1 mL, 9.1 mmol) in CH_2Cl_2 was added at -78 °C under N_2 to **22a** (0.45 g, 0.91 mmol) in CH_2Cl_2 (100 mL). The dark brown solution was allowed to stir at -78 °C for 0.5 h and allowed to warm to 0 °C for 2 h. A saturated solution of NaHCO_3 (100 mL) was cautiously added, and the biphasic mixture was extracted with EtOAc (3×150 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide a brown oil. The oil was purified using medium pressure column chromatography on silica gel using CHCl_3 –MeOH– NH_4OH (8:1.8:0.2) as an eluent to provide a 0.43 g (98%) of **9a** tan semisolid. The solid was recrystallized from acetone–petroleum ether to afford **9a** as white needles: mp 133 – 135 °C; $[\alpha]_D^{22} +108.7$ °C, (c 0.20, MeOH). ^1H NMR (CD_3OD) δ 0.69–0.74 (m, 9H), 0.89–0.98 (m, 1H), 1.28 (s, 3H), 1.52–1.59 (d, $J = 12.9\text{ Hz}$, 1H), 1.64–1.68 (m, 1H), 1.94–1.96 (m, 1H), 2.17–2.47 (m, 4H), 2.58–2.62 (d, $J = 11.3\text{ Hz}$, 1H), 2.72–2.75 (d, $J = 11.3\text{ Hz}$, 1H), 2.89–2.96 (dd, $J = 5.3, 15\text{ Hz}$, 1H), 3.11–3.18 (dd, $J = 7.54, 14.3\text{ Hz}$, 1H), 3.62–3.77 (m, 3H), 3.83–3.90 (m, 1H), 6.54–6.65 (m, 3H), 6.71–6.76 (m, 2H), 6.91–6.94 (d, $J = 8.2\text{ Hz}$, 1H), 7.06–7.11 (t, $J = 7.9\text{ Hz}$, 1H). Anal. ($\text{C}_{28}\text{H}_{38}\text{N}_2\text{O}_3\text{S} \cdot 0.25\text{ H}_2\text{O}$) C, H, N.

7-Hydroxyisothiochroman-3(-)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide Hydrochloride (9b)

A 1.0 M solution of BBr_3 (9.0 mL, 9.0 mmol) in CH_2Cl_2 was added at -78 °C under N_2 to **22b** (0.44 g, 0.90 mmol) in CH_2Cl_2 (100 mL). The dark brown solution was allowed to stir at -78 °C for 0.5 h and allowed to warm to 0 °C for 2 h. A saturated solution of NaHCO_3 (100 mL) was cautiously added, and the biphasic mixture was extracted with EtOAc (3×150 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide a brown oil. The oil was purified using medium pressure column chromatography on silica gel using CHCl_3 –MeOH– NH_4OH (8:1.8:0.2) as an eluent to provide 0.40 g (93%) of **9b** as a tan semisolid. ^1H NMR (CD_3OD) δ 0.71–0.74 (d, $J = 6.8\text{ Hz}$, 3H), 0.83–0.85 (d, $J = 6.8\text{ Hz}$, 3H), 0.88–0.90 (d, $J = 6.8\text{ Hz}$, 3H), 1.06–1.13 (m, 1H), 1.26 (s, 3H), 1.50–1.54 (d, $J = 12.4\text{ Hz}$, 1H), 1.79–1.94 (m, 2H), 2.15–2.39 (m, 4H), 2.48 (brs, 1H), 2.71–2.75 (d, $J = 11\text{ Hz}$, 1H), 2.97–3.10 (m, 2H), 3.58–3.78 (m, 3H), 3.85–3.91 (m, 1H), 6.57–6.60 (d, $J = 7.9\text{ Hz}$, 1H), 6.63 (m, 2H), 6.73 (m, 2H), 6.95–6.98 (d, $J = 8.2\text{ Hz}$, 1H), 7.06–7.12 (t, $J = 7.9\text{ Hz}$, 1H). The hydrochloride salt was prepared by adding a 1.0

M solution of HCl in Et₂O to **9b** in MeOH. The solution was concentrated under reduced pressure and recrystallized from EtOH–Et₂O to provide **9b**•HCl as white cubes: mp 224–227 °C (191–194 °C softens), [α]²²_D +62.1 °C, (c 0.38, MeOH). Anal. C, H, N.

7-Hydroxy-2-oxo-2-isothiochroman-3(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (10a,b) Resorcyate

3-Chloroperoxybenzoic acid (0.94 g, 0.41 mmol) was added to an ice-cold solution of **9a** (0.20 g, 0.41 mmol) in CH₂Cl₂ (20 mL). The solution was allowed to stir at 0 °C for 30 min and was quenched by the addition of saturated sodium bicarbonate. The slurry was extracted with CH₂Cl₂ (3 × 30 mL), dried (MgSO₄), and concentrated under reduced pressure to afford a mixture of diastereomers as a pale yellow oil. The diastereomers were separated by silica gel chromatography using CHCl₃–MeOH–NH₄OH (8:1.8:0.2) as the eluent to provide **10a** (first to elute, 28 mg, 14 %) and **10b** (second to elute, 21 mg, 10%) as pale yellow oils. Additional product was collected as a mixture of diastereomers.

7-Hydroxy-2-oxo-2-isothiochroman-3(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (10a) Resorcyate

The first spot to elute off the column was converted to the resorcyate salt by dissolving 3,5-dihydroxybenzoic acid (1.1 eq) in acetone and adding the amine in acetone. The solution was concentrated, and the solid was recrystallized from EtOAc and hexane to provide 17 mg of **10a** as a white solid: mp 170–173 °C; [α]²²_D +4.7 °C, (c 0.11, MeOH). ¹H NMR (CD₃OD) δ 0.80 (d, *J* = 6.8 Hz, 3H), 1.01 (m, 6H), 1.27–1.40 (m, 4H), 1.72 (d, 1H), 1.85 (m, 1H), 2.13 (m, 1H), 2.41 (m, 1H), 2.79–2.86 (m, 3H), 3.0–3.08 (m, 3H), 3.18–3.23 (m, 1H), 3.62 (dd, *J* = 6, 9 Hz, 1H), 4.10–4.16 (m, 3H), 6.38 (dd, 1H), 6.59–6.79 (m, 5H), 6.91 (dd, 1H), 6.96–6.99 (d, *J* = 9 Hz, 1H), 7.10–7.15 (m, 2H). Anal. (C₃₅H₄₄N₂O₈S•1.5 H₂O) C, H, N.

7-Hydroxy-2-oxo-2-isothiochroman-3(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (10b) Resorcyate

The second spot to elute off the column was converted to the resorcyate salt by dissolving 3,5-dihydroxybenzoic acid (1.1 eq) in acetone and adding the amine in acetone. The solution was concentrated, and the solid was recrystallized from EtOAc and hexane to provide 12 mg of **10b** resorcyate as a white solid: mp 186–189 °C; [α]²²_D +102.0 °C, (c 0.15, MeOH). ¹H NMR (CD₃OD) δ 0.82 (dd, *J* = 6, 3 Hz, 3H), 0.97 (m, 6H), 1.26 (dd, *J* = 4, 12 Hz, 1H), 1.36 (s, 3H), 1.72–1.76 (d, 8 Hz, 1H), 1.90 (m, 1H), 2.18 (m, 1H), 2.46 (m, 1H), 2.91–3.32 (m, 6H), 3.51 (m, 1H), 3.72–3.87 (m, 1H), 4.0–4.33 (m, 3H), 6.37 (dd, *J* = 6, 6 Hz, 1H), 6.60–6.78 (m, 5H), 6.91 (d, *J* = 3 Hz, 2H), 7.01–7.15 (m, 2H). Anal. (C₃₅H₄₄N₂O₈S•1.25 H₂O) C, H, N.

2(+)-6-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic Acid [(+)-13]

A 30% solution of hydrogen peroxide (6.96 mmol, 0.24 mL) in H₂O was added at 0 °C to a solution of **15a** (0.42 g, 1.16 mmol) in 3:1 THF–H₂O (25 mL). Lithium hydroxide hydrate (0.098 g, 2.32 mmol) was added to the solution in portions. The suspension was allowed to stir for 0.5 h at 0 °C and for 2 h at room temperature. A 1.5 N solution of Na₂SO₃ (15 mL) was added in a dropwise manner, and the biphasic solution was basified (pH $\approx$ 9) with saturated sodium bicarbonate solution. The solution was extracted (2 × 50 mL) with EtOAc, made acidic to pH 3 with HCl (10 M solution), and extracted (3 × 100 mL) with CH₂Cl₂. The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a white solid. The solid was recrystallized from EtOAc–petroleum ether to provide 0.22 g (92%) of (+)-**13** as white needles: mp 129–130 °C; [α]²²_D +57.27 °C, (c 0.22, CHCl₃). ¹H-NMR (CDCl₃) δ 1.87–1.90 (m, 1H), 2.20–2.25 (m, 1H), 2.74–2.98 (m,

5H), 3.77 (s, 3H), 6.63 (s, 1H), 6.68–6.72 (dd, $J = 2.7, 8.4$ Hz, 1H), 7.0–7.03 (d, $J = 8.4$ Hz, 1H).

2(-)-6-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic Acid [(-)-13]

A 30% solution of hydrogen peroxide (3.3 mmol, 0.11 mL) in H₂O was added at 0 °C to a solution of **15b** (0.20 g, 0.55 mmol) in THF–H₂O (3:1) (15 mL). Lithium hydroxide hydrate (0.046 g, 1.10 mmol) was added to the solution in portions. The suspension was allowed to stir for 0.5 h at 0 °C and for 2 h at room temperature. A 1.5 N solution of Na₂SO₃ (10 mL) was added in a dropwise manner, and the biphasic solution was basified (pH $\approx$ 10) with saturated sodium bicarbonate solution. The solution was extracted (2 $\times$ 50 mL) with EtOAc, made acidic to pH 3 with HCl (10 M solution), and extracted (3 $\times$ 100 mL) with CH₂Cl₂. The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a white solid. The solid was recrystallized from EtOAc–petroleum ether to provide 0.102 g (90%) of (-)-**13** as white needles: mp 121–122 °C; $[\alpha]_D^{22}$ -56.9 °C (c 0.25, CHCl₃). ¹H NMR (CDCl₃) δ 1.87–1.90 (m, 1H), 2.20–2.25 (m, 1H), 2.74–2.98 (m, 5H), 3.77 (s, 3H), 6.63 (s, 1H), 6.68–6.72 (dd, $J = 2.7, 8.4$ Hz, 1H), 7.0–7.03 (d, $J = 8.4$ Hz, 1H).

(3a*R*-cis)-3-(6-Methoxy-1,2,3,4-tetrahydronaphthalene-2(+ and -)-carbonyl)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (15a,b)

A 2.0 M solution of thionyl chloride (7.25 mL, 14.3 mmol) in CH₂Cl₂ was added to a solution of ($\pm$)-**13**²⁹ (0.29 g, 1.43 mmol) in toluene (20 mL). The solution was heated at reflux for 8 h, cooled to room temperature, and concentrated under reduced pressure to provide 6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carbonyl chloride as a tan solid. In a separate flask, a 0.50 M solution of ethyl lithium (3.0 mL, 1.50 mL) in benzene–cyclohexane (90:10) was added to a solution of (3a*R*-cis)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (0.25 g, 1.43 mmol) in THF (20 mL) at 0 °C under N₂. The suspension was allowed to stir at 0 °C for 0.5 h and was cooled to -78 °C. A solution of 6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carbonyl chloride (0.29 g, 1.43 mmol) in THF (10 mL) was then added in a dropwise manner to the -78 °C slurry. The resulting slurry was allowed to warm to room temperature over 2 h, and water (100 mL) was added. The suspension was extracted with CH₂Cl₂ (3 $\times$ 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a mixture of **15a** and **15b** as a tan solid. The two compounds were separated using silica gel medium pressure column chromatography petroleum ether–Et₂O (70:30) to provide each of the diastereomers in approximately 50% theoretical yield. The yield improves with additional chromatography. The less polar spot was later identified as the (+) isomer while the more polar was (-).

(3a*R*-cis)-3-(6-Methoxy-1,2,3,4-tetrahydronaphthalene-2(+)-carbonyl)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (15a)

The solid was recrystallized from EtOAc–petroleum ether to provide 0.12 g (46%) of **15a** as a white solid: mp 168–169 °C. ¹H-NMR (CDCl₃) δ 1.80–1.85 (m, 1H), 2.10–2.21 (m, 1H), 2.71–3.13 (m, 4H), 3.38 (d, $J = 3.3$ Hz, 2H), 3.76 (s, 3H), 3.84 (m, 1H), 5.27 (m, 1H), 5.96–5.99 (d, $J = 9$ Hz, 1H), 6.62 (s, 1H), 6.70–6.71 (dd, $J = 2.4, 8.1$ Hz, 1H), 6.99–7.04 (dd, $J = 3.6, 8.4$ Hz, 1H), 7.24–7.32 (m, 3H), 7.57–7.60 (d, $J = 7.5$ Hz, 1H).

(3a*R*-cis)-3-(6-Methoxy-1,2,3,4-tetrahydronaphthalene-2(-)-carbonyl)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (15b)

The solid was recrystallized from EtOAc–petroleum ether to provide 0.13 g (50%) of **15b** as a white solid: mp 162–164 °C. ¹H-NMR (CDCl₃) δ 1.85–1.98 (m, 1H), 2.12–2.18 (m, 1H),

2.84–2.95 (m, 4H), 3.40–3.41 (d, $J = 3.3$ Hz, 2H), 3.77 (s, 3H), 3.85–3.95 (m, 1H), 5.28–5.33 (m, 1H), 5.97–5.99 (d, $J = 6.9$ Hz, 1H), 6.57–6.69 (m, 2H), 6.95–6.98 (d, $J = 8.4$ Hz, 1H), 7.26–7.42 (m, 3H), 7.60–7.62 (d, $J = 7.5$ Hz, 1H).

6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (16a)

2(+)-6-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [(+)-**13**, 0.22 g, 1.07 mmol] was added under N₂ to a solution of BOP (0.47 g, 1.07 mmol), TEA (0.23 g, 2.35 mmol), and **12**²⁷ (0.31 g, 1.07 mmol) in anhydrous THF (50 mL). The solution was allowed to stir at room temperature for 6 h, and a saturated NaHCO₃ solution (100 mL) was added. The biphasic mixture was extracted with EtOAc (3 × 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide an oil. The oil was purified using medium pressure column chromatography on silica gel using CHCl₃–MeOH–NH₄OH (9:0.8:0.2) at the eluent to provide 0.39 g (77%) of **16a** as a colorless oil. ¹H NMR (CDCl₃) δ ppm 0.72 (d, $J = 6.78$ Hz, 3 H), 0.82–0.96 (m, 6 H), 1.26 (s, 3 H), 1.55 (d, $J = 12.43$ Hz, 1 H), 1.78–2.07 (m, 4 H), 2.18–2.88 (m, 12 H), 3.73 (s, 3 H), 4.00–4.16 (m, 1 H), 6.05 (d, $J = 7.54$ Hz, 1 H), 6.57 (d, $J = 2.64$ Hz, 1 H), 6.62–6.77 (m, 3 H), 6.84 (m, 1 H), 6.93 (d, $J = 8.67$ Hz, 1 H), 7.11 (t, $J = 7.91$ Hz, 1 H).

6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2(-)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-*trans*-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (16b)

2(-)-6-Methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid [(-)-**13**, 0.31 g, 1.48 mmol] was added under N₂ to a solution of BOP (0.65 g, 1.48 mmol), TEA (0.33 g, 3.26 mmol), and **12** (0.43 g, 1.48 mmol) in anhydrous THF (65 mL). The solution was allowed to stir at room temperature for 6 h, and a saturated NaHCO₃ solution (100 mL) was added. The biphasic mixture was extracted with EtOAc (3 × 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide an oil. The oil was purified using medium pressure column chromatography on silica gel using CHCl₃–MeOH–NH₄OH (9:0.8:0.2) as the eluent to provide 0.70 g (98%) of **16b** as a colorless oil. ¹H NMR (CDCl₃) δ ppm 0.66–0.78 (d, $J = 6.9$ Hz, 3 H), 0.83–0.97 (m, 6 H), 1.25 (s, 3 H), 1.53 (d, $J = 12.43$ Hz, 1 H), 1.78–2.10 (m, 4 H), 2.20–2.97 (m, 12 H), 3.73 (s, 3 H), 4.03 (m, 1 H), 6.03 (d, $J = 7.54$ Hz, 1 H), 6.57 (d, $J = 2.26$ Hz, 1 H), 6.61–6.75 (m, 3 H), 6.82 (m, 1 H), 6.90 (d, $J = 8.29$ Hz, 1 H), 7.10 (t, $J = 7.72$ Hz, 1 H).

7-Methoxy-isothiochroman-4-one-3-carboxylic Acid Methyl Ester (18)

A 2.0 M solution of LDA in heptane–THF–ethylbenzene (1.61 mL, 3.21 mmol) was added in a dropwise manner to a solution of 7-methoxyisothiochroman-4-one (**17**)³¹ (0.50 g, 2.57 mmol) in THF (50 mL) at -78 °C under N₂. After 30 min at -78 °C, HMPA (0.46 g, 2.57 mmol) and methyl cyanoformate (0.27 g, 3.21 mmol) were added, and the yellow solution was allowed to stir at -78 °C for 30 min. The solution was then allowed to warm to room temperature, and a saturated solution of NH₄Cl (100 mL) was added. The slurry was extracted with EtOAc (3 × 75 mL), and the organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a bright yellow oil. The oil was purified on silica gel medium pressure chromatography using petroleum ether–EtOAc (9:1) as the eluent to provide 0.51 g (78%) of **18** as a bright yellow oil. ¹H-NMR (CDCl₃) δ 3.73 (s, 2H), 3.83 (s, 3H), 3.85 (s, 3H), 6.67 (d, $J = 3$ Hz, 1H), 6.45 (dd, $J = 3, 8.7$ Hz, 1H), 7.80 (d, $J = 8.7$ Hz, 1H), 12.52 (s, 1H).

7-Methoxy-isothiochroman-3-carboxylic Acid Methyl Ester (19)

Triethylsilane (8.08 mmol, 0.94 g) was added to a solution of **18** (0.51 g, 2.02 mmol) in trifluoroacetic acid (15 mL) at room temperature under N₂. The reaction mixture was

allowed to stir at room temperature for 2 h and was concentrated under reduced pressure. The resulting oil was dissolved in EtOAc (100 mL) and washed with a saturated NaHCO₃ solution (3 × 75 mL). The organic extracts were combined, dried (MgSO₄), and concentrated to provide an oil. The oil was purified by silica gel medium pressure chromatography using petroleum ether–EtOAc (9:1) as the eluent to provide 0.34 g, (70%) of **19** as a pale yellow oil. ¹H NMR (CDCl₃) δ 3.14 (m, 2H), 3.58–3.63 (d, *J* = 15 Hz, 1H), 3.73–3.86 (m, 8H), 6.70 (d, *J* = 3 Hz, 1H), 6.75 (dd, *J* = 3, 9 Hz, 1H), 7.10 (d, *J* = 9 Hz, 1H).

7-Methoxy-isothiochroman-3-carboxylic Acid [(±)-**20**]

Potassium hydroxide (0.80 g, 14.3 mmol) was added to a solution of **19** (0.34 g, 1.43 mmol) in MeOH (50 mL). The solution was heated at 60 °C for 2 h, cooled to room temperature, and diluted with H₂O (100 mL). The solution was made acidic with 6 N HCl and extracted with EtOAc (3 × 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated to give 0.28 g (88%) of (±)-**20** as a pale yellow solid. The solid was used in the next step without further purification.

3(+)-7-Methoxy-isothiochroman-3-carboxylic Acid [(+)-**20**]

Lithium hydroxide hydrate (0.093 g, 2.2 mmol) was added at 0 °C to a solution of **21a** (0.42 g, 1.10 mmol) in THF–H₂O (3:1) (25 mL). The suspension was allowed to stir for 0.5 h at 0 °C. The reaction was made basic (pH ≈ 9) with saturated sodium bicarbonate solution, and the solution was extracted with Et₂O (1 × 100 mL), made acidic to pH 3 with HCl (6 N solution), and extracted with EtOAc (3 × 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide 0.25 g (100%) of (+)-**20** as a white solid. The solid was recrystallized from toluene–petroleum ether to provide (+)-**20** as tan cubes: mp 117–118 °C; [α]_D²² +98.3 °C (c 0.24, MeOH). ¹H NMR (CD₃OD) δ 2.97–3.01 (dd, *J* = 9.3, 15 Hz, 1H), 3.10–3.17 (dd, *J* = 5.1, 15.3, 1H), 3.63–3.88 (m, 6H), 6.75–6.77 (m, 2H), 7.08–7.11 (d, *J* = 8.2 Hz, 1H).

3(-)-7-Methoxy-isothiochroman-3-carboxylic Acid [(-)-**20**]

Lithium hydroxide hydrate (0.055 g, 1.32 mmol) was added at 0 °C to a solution of **21b** (0.25 g, 0.66 mmol) in THF–H₂O (3:1) (15 mL). The suspension was allowed to stir for 0.5 h at 0 °C. The reaction was made basic (pH ≈ 9) with saturated sodium bicarbonate solution, and the solution was extracted with Et₂O (1 × 100 mL), made acidic to pH 3 with 6 N HCl, and extracted with EtOAc (3 × 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide 0.14 g (92%) of (-)-**20** as a white solid (0.136 g, 92%). The solid was recrystallized from toluene–petroleum ether to provide (-)-**20** as pale yellow needles: mp 121–122 °C; [α]_D²² -100.8 °C (c 0.26, MeOH). ¹H NMR (CD₃OD) δ 2.97–3.01 (dd, *J* = 9.3, 15 Hz, 1H), 3.10–3.17 (dd, *J* = 5.1, 15.3, 1H), 3.63–3.88 (m, 6H), 6.75–6.77 (m, 2H), 7.08–7.11 (d, *J* = 8.2 Hz, 1H).

(3a*R*-*cis*)-3-(7-Methoxy-isothiochroman-3(+ and -)-carbonyl)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (**21a,b**)

A 2.0 M solution of oxalyl chloride (3.57 mL, 7.14 mmol) in CH₂Cl₂ was added under N₂ to a solution of (±)-**20** (0.80 g, 3.57 mmol) and a drop of DMF in CH₂Cl₂ (100 mL). The solution was allowed to stir at room temperature for 3 h and was concentrated under reduced pressure to provide 7-methoxy-isothiochroman-3-carbonyl chloride as a tan oil. 7-Methoxy-isothiochroman-3-carbonyl chloride was used in the next step without further purification. In a separate flask, a 0.50 M solution of ethyl lithium (8.6 mL, 4.28 mmol) in benzene–cyclohexane 90:10 was added to a solution of (3a*R*-*cis*)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (**14**, 0.75 g, 4.28 mmol) in THF (100 mL) at 0 °C under N₂. The suspension was allowed to stir at 0 °C for 0.5 h and was then cooled to -78 °C. A solution of 7-

methoxyisothiochroman-3-carbonyl chloride (0.86 g, 3.57 mmol) in THF (10 mL) was added in a dropwise manner to the -78 °C slurry. The resulting slurry was allowed to warm to room temperature over 2 h, and water (150 mL) was then added. The suspension was extracted with CH₂Cl₂ (3 × 150 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a mixture of **21a** and **21b** as a tan solid. The mixture was separated by silica gel medium pressure column chromatography using petroleum ether–Et₂O (60:40) as the eluent to provide each of the diastereomers in 62% [**21a**, (+)-isomer] and 37% [**21b**, (-)-isomer] theoretical yield. The yield improves with additional chromatography. The higher R_f spot on TLC was identified as the (+)-isomer while the more polar spot was the (-)-isomer.

(3a*R*)-cis)-3-(7-Methoxy-isothiochroman-3(+)-carbonyl)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (21a**)**

The solid was recrystallized from EtOAc–petroleum ether to provide 0.42 g (62%) of **21a** as a white solid: mp 146–147 °C. ¹H-NMR (CDCl₃) δ 3.09–3.16 (dd, *J* = 6, 15.6 Hz, 1H), 3.20–3.28 (dd, *J* = 7.2, 15.3 Hz, 1H), 3.38–3.39 (d, *J* = 3.6 Hz, 2H), 3.59–3.64 (d, *J* = 15 Hz, 1H), 3.79 (s, 3H), 3.85–3.90 (d, *J* = 15 Hz, 1H), 4.97–5.01 (m, 1H), 5.30–5.35 (m, 1H), 5.92–5.95 (d, *J* = 7 Hz, 1H), 6.71–6.72 (d, *J* = 2.7 Hz, 1H), 6.75–6.79 (dd, *J* = 2.4, 8.4 Hz, 1H), 7.06–7.09 (d, *J* = 8.4 Hz, 1H), 7.23–7.38 (m, 3H), 7.58–7.61 (d, *J* = 7.5 Hz, 1H).

(3a*R*)-cis)-3-(7-Methoxy-isothiochroman-3(-)-carbonyl)-3,3a,8,8a-tetrahydro-2*H*-indeno[1,2-*d*]oxazol-2-one (21b**)**

The solid was recrystallized from EtOAc–petroleum ether to provide 0.25 g (37%) of **21b** as a white solid: mp 176–178 °C. ¹H-NMR (CDCl₃) δ 3.14–3.19 (dd, *J* = 6, 12.6 Hz, 1H), 3.24–3.29 (dd, *J* = 7.5, 15.3 Hz, 1H), 3.39–3.40 (d, *J* = 3.6 Hz, 2H), 3.48–3.55 (d, *J* = 15 Hz, 1H), 3.79 (s, 3H), 3.83–3.88 (d, *J* = 15 Hz, 1H), 4.91–4.95 (m, 1H), 5.29–5.33 (m, 1H), 5.96–5.99 (d, *J* = 7 Hz, 1H), 6.71–6.72 (d, *J* = 2.7 Hz, 1H), 6.76–6.80 (dd, *J* = 2.4, 8.4 Hz, 1H), 7.10–7.12 (d, *J* = 8.4 Hz, 1H), 7.26–7.38 (m, 3H), 7.58–7.61 (d, *J* = 7.5 Hz, 1H).

7-Methoxy-isothiochroman-3(+)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*)-(4*R*)-trans-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (22a**)**

3(+)-7-Methoxyisothiochroman-3-carboxylic acid [(+)-**20**, (0.25 g, 1.12 mmol)] was added under N₂ to a solution of BOP (0.50 g, 1.12 mmol), TEA (0.23 g, 2.24 mmol), and **12**²⁷ (0.33 g, 1.12 mmol) in anhydrous THF (50 mL). The solution was allowed to stir at room temperature for 6 h, and a saturated NaHCO₃ solution (100 mL) was added. The biphasic mixture was extracted with EtOAc (3 × 100 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide an oil. The oil was purified using medium pressure column chromatography using CHCl₃–MeOH–NH₄OH (9:0.8:0.2) to provide 0.5 g (81%) of **22a** as a pale yellow semisolid. ¹H NMR (CDCl₃) δ 0.49–0.55 (m, 6H), 0.67–0.69 (d, *J* = 6 Hz, 3H), 1.24 (s, 3H), 1.48–1.52 (d, *J* = 12 Hz, 1H), 1.62–1.70 (m, 1H), 1.86–1.88 (m, 1H), 2.14–2.52 (m, 6H), 2.61–2.71 (m, 2H), 2.89–2.95 (dd, *J* = 5.1, 14.4 Hz, 1H), 3.31–3.38 (dd, *J* = 5.4, 14.4 Hz, 1H), 3.57–3.62 (d, *J* = 13.8 Hz, 1H), 3.65–3.69 (d, *J* = 13.8 Hz, 1H), 3.74 (s, 3H), 3.84–3.87 (m, 1H), 6.70–6.72 (m, 3H), 6.84–6.89 (m, 2H), 7.03–7.12 (m, 2H).

7-Methoxy-isothiochroman-3(-)-carboxylic acid-{1-[4-(3-hydroxyphenyl)-(3*R*,4*R*)-trans-dimethyl-piperidinylmethyl]-(2*S*)-methylpropyl}amide (22b**)**

3(-)-7-Methoxy-isothiochroman-3-carboxylic acid [(-)-**20**, 0.24 g, 1.07 mmol] was added under N₂ to a solution of BOP (0.47 g, 1.07 mmol), TEA (0.21 g, 2.14 mmol), and **12**²⁷ (0.31 g, 1.07 mmol) in anhydrous THF (50 mL). The solution was allowed to stir at room temperature for 6 h, and a saturated NaHCO₃ solution (100 mL) was added. The biphasic

mixture was extracted with EtOAc (3×100 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide an oil. The oil was purified by silica gel medium pressure column chromatography using CHCl_3 – MeOH – NH_4OH (9:0.8:0.2) as the eluent to provide 0.44 g (84%) of **22b** as a pale yellow semisolid. ^1H NMR (CDCl_3) δ 0.65–0.68 (d, $J = 6.9$ Hz, 3H), 0.77–0.79 (d, $J = 4.2$ Hz, 3H), 0.84–0.86 (d, $J = 6.6$ Hz, 3H), 1.27 (s, 3H), 1.47–1.51 (d, $J = 12.3$ Hz, 1H), 1.80–2.70 (m, 11H), 3.03–3.09 (dd, $J = 5.4, 14.7$ Hz, 1H), 3.17–3.24 (dd, $J = 6.3, 14.4$ Hz, 1H), 3.60–3.65 (d, $J = 14.1$ Hz, 1H), 3.67–3.72 (d, $J = 14.1$ Hz, 1H), 3.77 (s, 3H), 3.83–3.87 (m, 1H), 6.59–6.83 (m, 5H), 7.05–7.16 (m, 2H).

7-Methoxy-1*H*-isochromen-4(3*H*)-one (**24**)

Oxalyl chloride (92.5 mL, 2.0 M in CH_2Cl_2 , 185 mmol) was added dropwise to a solution of (3-methoxybenzyloxy)acetic acid (**23**)³⁴ (23.2 g, 0.12 mol) in CH_2Cl_2 (850 mL) at 0 °C under N_2 , and a few drops of DMF were added to initiate the reaction. The reaction mixture was stirred for 2 h at room temperature and was concentrated to give a brown oil. Chlorobenzene (500 mL) was then added, and the mixture was allowed to stir using a mechanical stirrer. The mixture was cooled to 0 °C in an ice bath, SnCl_4 (29 mL, 246.8 mmol) was added slowly, and the reaction mixture was allowed to stir at 0 °C under N_2 for 1 h. The reaction mixture was quenched with saturated NaHCO_3 (150 mL) and H_2O (150 mL) and then extracted with CH_2Cl_2 (3×250 mL). The combined organics were dried over NaSO_4 , and the solvent was removed under reduced pressure to afford crude compound which was purified by silica gel medium pressure column chromatography using 10–40% EtOAc in hexane to give 10.9 g (52%) of **24** as a white solid. ^1H NMR (CDCl_3) δ 8.02 (d, $J = 8.6$ Hz, 1H), 6.92 (d, $J = 7.9$ Hz, 1H), 6.67 (s, 1H), 4.85 (s, 2H), 4.33 (s, 2H), 3.88 (s, 1H). ^{13}C NMR (CDCl_3 , 75MHz) δ 193.1, 164.6, 144.6, 129.4, 123.6, 114.5, 109.1, 73.7, 68.4, 56.0. LCMS (APCI) m/z ($\text{M}+\text{H}$)⁺ 179.2.

7-Hydroxy-1*H*-isochromen-4(3*H*)-one (**25**)

7-Methoxy-1*H*-isochromen-4(3*H*)-one (**24**, 11.0 g, 0.062 mol) was dissolved in DMF (320 mL), and EtSNa (7.8 g, 0.093 mol) was added. The reaction mixture was heated at reflux for 3 h, H_2O (450 mL) was added, and the mixture was extracted with EtOAc (300 mL). The aqueous layer was cooled, acidified to pH $\approx$ 4 with 1 M HCl , and then extracted with EtOAc (3×300 mL). The combined organics were washed with bleach (200 mL) and dried over sodium sulfate, and the solvent was removed under reduced pressure to afford crude product which was purified by silica gel medium pressure column chromatography using 10–50% EtOAc in hexane as the eluent to give 7.2 g (71%) of **25** as a colorless solid. ^1H NMR (CD_3OD) δ 7.85–7.80 (m, 1H), 6.77 (d, $J = 6.4$ Hz, 1H), 6.6 (s, 1H), 4.76 (s, 3H), 4.22 (s, 2H). ^{13}C NMR (CD_3OD , 75MHz) δ 195.5, 165.2, 147.0, 130.3, 123.3, 116.8, 111.7, 74.4, 69.2. LCMS (ESI) m/z ($\text{M}+\text{H}$)⁺; 163.4 ($\text{M}-\text{H}$)⁺.

7-(Methoxymethoxy)-1*H*-isochromen-4(3*H*)-one (**26**)

7-Hydroxy-1*H*-isochromen-4(3*H*)-one (**25**, 7.0 g, 0.43 mol) was dissolved in CH_2Cl_2 (350 mL), and the solution was cooled to 0 °C under N_2 . *i*- Pr_2EtN (8.3g, 0.064 mol) was added, and then MOMCl (5.15 g, 0.064 mol) was added slowly. The reaction mixture was stirred for 8 h at room temperature, and saturated NaHCO_3 (200 mL) was added. The suspension was extracted with EtOAc (3×250 mL), the combined organics were dried over sodium sulfate, and the solvent was removed under reduced pressure. The solid was purified by silica gel medium pressure column chromatography using 10–40% EtOAc in hexane as the eluent to give 7.8 g (88%) of **26** as a colorless solid. ^1H NMR (CDCl_3) δ 8.02 (d, $J = 8.6$ Hz, 1H), 7.03 (d, $J = 8.6$ Hz, 1H), 6.84 (s, 1H), 5.24 (s, 2H), 4.85 (s, 2H), 4.33 (s, 2H), 3.49 (s, 3H). ^{13}C NMR (CDCl_3 , 75MHz) δ 192.8, 161.8, 144.2, 128.9, 124.0, 116.1, 110.7, 94.1, 73.4, 68.1, 56.4. LCMS (APCI) m/z ($\text{M}+\text{H}$)⁺.

Methyl 7-(methoxymethoxy)-4-oxo-3,4-dihydro-1H-isochromen-3-carboxylate (27)

LDA (31 mL, 2.0 M in THF–heptane–ethylbenzene, 62.0 mmol) was then added to a solution of **26** (6.6 g, 0.032 mol) in THF (400 mL) at -78°C. The mixture was stirred at -78 °C for 30 min, HMPA (5.74 g, 5.6 mL, 0.032mol) was added followed by methylcyanoformate (5.4 g, 0.064 mol). The reaction mixture was stirred at -78 C for 2 h and warmed to room temperature. The reaction mixture was quenched with saturated NH₄Cl (250 mL) and then extracted with EtOAc (3 × 300 mL). The combined organics were dried over sodium sulfate, and the solvent was removed under reduced pressure to afford crude compound which was purified by silica gel medium pressure column chromatography using 10–30% EtOAc in hexane as eluent to give 4.35 g (52%) of **27** as a colorless solid. NMR shows a mixture of ketone and enol tautomers. ¹H NMR (CDCl₃) δ 8.02 (d, *J* = 8.7 Hz, 0.7 H), 7.61 (d, *J* = 8.5 Hz, 0.2H), 7.03 (d, *J* = 8.7 Hz, 1H), 6.81 (s, 1H), 5.24 (s, 1H), 5.23 (s, 2H), 4.97–4.85 (m, 2H), 3.91 (s, 0.7H), 3.84 (s, 2.5H), 3.48 (s, 3H). ¹³C NMR (CDCl₃, 75MHz) δ 187.1, 166.9, 162.3, 143.5, 129.6, 124.4, 116.5, 110.5, 94.2, 80.5, 65.9, 56.4, 52.8. LCMS (ESI) *m/z* 267.1(M+H)⁺.

Methyl 7-hydroxy-3,4-dihydro-1H-isochromene-3-carboxylate (28)

TFA (80 mL) was added to **27** (4.3 g, 0.016 mol) at 0 °C, and Et₃SiH (7.52 g, 0.065 mol) was added. The reaction mixture was stirred at room temperature for 2 h and then was concentrated under reduced pressure. Saturated NaHCO₃ (100 mL) was added, and the mixture was extracted with EtOAc (3 × 150 mL). The combined organics were dried (Na₂SO₄), and the solvent was removed under reduced pressure to afford crude compound which was purified by silica gel medium pressure column chromatography using 10–40% EtOAc in hexane as eluent to give 2.22 g (66%) of **28** as a colorless solid. ¹H NMR (CDCl₃) δ 6.99 (d, *J* = 8.0 Hz, 1H), 6.70 (d, *J* = 8.1 Hz, 1H), 6.48 (s, 1H), 5.76 (s, 1H), 4.91 (d, *J* = 15.0 Hz, 1H), 4.78 (d, *J* = 15.0Hz, 1H), 4.36 (t, *J* = 7.0 Hz, 1H), 3.82 (s, 3H), 2.99 (d, *J* = 6.9 Hz, 2H). ¹³C NMR (CDCl₃, 75MHz) δ 171.9, 154.4, 134.8, 129.9, 123.3, 114.4, 110.7, 73.6, 67.8, 52.4, 30.1. LCMS (ESI) *m/z* 209.3 (M+H)⁺; 231.5 (M+Na)⁺.

7-Hydroxy-3,4-dihydro-1H-isochromene-3-carboxylic Acid (29)

Lithium hydroxide hydrate (45 mg, 1.08 mmol) was added to a solution of **28** (0.100 g, 0.48 mmol) in a mixture of THF–H₂O–MeOH (1:1:1) (25 mL) at 0 °C. The solution was allowed to stir for 1 h and warmed to room temperature. A 1 N solution of HCl was added until the mixture was acidic and was then extracted with CHCl₃ (3 × 50 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide 0.75 g (82%) of (±)-**29** as a white solid. This solid was used in the next step without further purification. ¹H NMR (CD₃OD) δ 2.96, (m, 3H), 4.32 (dd, *J* = 3, 9 Hz, 1H), 4.74 (m, 2H), 6.46 (s, 1H), 6.63 (d, *J* = 9 Hz, 1H), 6.95 (d, *J* = 9 Hz, 1H).

Compounds 3 and 2 Alignment

Three-dimensional structures of **3** and **2** were built using the Sybyl fragment library and optimized using the MMFF94 force-field and charges. A systematic conformational search followed by a multi-fit flexible structural alignment was performed using **2** as the rigid template (excepting the guanidinium group of **2** which was allowed to freely rotate during the multi-fit alignment). Six **2**-**3** atom pairs and a spring constant of 20 kcal/mol were used to align **3** to the **2** template. The atom pairs were the **3** and **2** phenolic ring centroid, **3** atoms 3, 4, 5, 3-methyl, 4-methyl paired with **2** atoms 14, 13, 15, 10, and 5 (morphine numbering). The centroid of the Tic aromatic ring of **3** was paired with the centroid of the guanidinium group of **2**. After alignment, a final energy minimization was performed using the MMFF94 force-field to allow the structure of **3** to relax to a local minimum energy conformation. This process was repeated for each of the 10 lowest energy conformations of **3** obtained from an

initial systematic conformational search in order to identify the lowest energy conformation of **3** that could provide a close alignment to the **2** pharmacophore template.

Evaluation of **7a** to Block U50,488-Induced Diuresis

Adult male Sprague-Dawley rats (Charles River Laboratories, Raleigh, NC, USA) were used for these studies. The test compound and U50,488 doses were prepared fresh in distilled deionized water (vehicle) and administered (1 mL/kg body weight) via subcutaneous injection. Six groups of four rats were used to evaluate each test compound: vehicle control; agonist control (10 mg/kg); test compound **7a** at 3, 10, or 30 mg/kg followed by agonist (10 mg/kg); and compound **7a** followed by vehicle (30 mg/kg). Each rat was weighed prior to dosing. One rat from each group was dosed in succession and the pattern repeated to distribute any effects of time of day across all groups. After dosing, each rat was placed into a metabolic chamber and urine output was collected hourly for 5 h. Urine output for each collection period was calculated as (urine + collection tube weight)-collection tube tare weight. The effect of test compound on total urine output was assessed by analysis of variance with repeated measures (subject within Group) and factors of Group and Time and their interaction, or one-way ANOVA, where appropriate. A univariate ANOVA was run only if a significant effect was observed following the multivariate ANOVA. Significance was assumed at $p < 0.05$ for the individual factors and $p < 0.1$ for their interaction.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the National Institute on Drug Abuse Grant DA09045.

References

1. Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTC, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. *Psychopharmacology (Berl)*. 2005; 183:118–126. [PubMed: 16184376]
2. Carey AN, Borozny K, Aldrich JV, McLaughlin JP. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist aroclon. *Eur J Pharmacol*. 2007; 569:84–89. [PubMed: 17568579]
3. Carroll FI, Harris LS, Aceto MD. Effects of JDTC, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. *Eur J Pharmacol*. 2005; 524:89–94. [PubMed: 16236279]
4. McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. *J Neurosci*. 2003; 23:5674–5683. [PubMed: 12843270]
5. Redila VA, Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. *Psychopharmacology (Berl)*. 2008; 200:59–70. [PubMed: 18575850]
6. Walker BM, Koob GF. Pharmacological evidence for a motivational role of κ -opioid systems in ethanol dependence. *Neuropsychopharmacology*. 2007; 1–10. [PubMed: 17019409]
7. Jackson KJ, Carroll FI, Negus SS, Damaj MI. Effect of the selective kappa-opioid receptor antagonist JDTC on nicotine antinociception, reward, and withdrawal in the mouse. *Psychopharmacology (Berl)*. 2010; 285–294. [PubMed: 20232057]

8. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. *J Neurochem.* 2004; 90:1258–1268. [PubMed: 15312181]
9. Zhang H, Shi YG, Woods JH, Watson SJ, Ko MC. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. *Eur J Pharmacol.* 2007; 570:89–96. [PubMed: 17601558]
10. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, Jones RM, Portoghese PS, Carlezon WA Jr. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. *J Pharmacol Exp Ther.* 2003; 305:323–330. [PubMed: 12649385]
11. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. Anxiolytic-Like Effects of κ -Opioid Receptor Antagonists in Models of Unlearned Learned Fear in Rats. *J Pharmacol Exp Ther.* 2007; 323:838–845. [PubMed: 17823306]
12. Jarosz PA. The effect of kappa opioid receptor antagonism on energy expenditure in the obese Zucker rat. *Biol Res Nurs.* 2007; 8:294–299. [PubMed: 17456590]
13. Calcagnetti DJ, Calcagnetti RL, Fanselow MS. Centrally administered opioid antagonists, nor-binaltorphimine, 16-methyl cyprenorphine and MR2266, suppress intake of a sweet solution. *Pharmacol Biochem Behav.* 1990; 35:69–73. [PubMed: 2315372]
14. Jewett DC, Grace MK, Jones RM, Billington CJ, Portoghese PS, Levine AS. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. *Brain Res.* 2001; 909:75–80. [PubMed: 11478923]
15. Bortolato M, Aru GN, Frau R, Orru M, Fa M, Manunta M, Puddu M, Mereu G, Gessa GL. Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats. *Biol Psychiatry.* 2005; 57:1550–1558. [PubMed: 15953492]
16. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective κ -opioid receptor antagonists. *Life Sci.* 1987; 40:1287–1292. [PubMed: 2882399]
17. Portoghese PS, Lipkowski AW, Takemori AE. Bimorphinans as highly selective, potent kappa opioid receptor antagonists. *J Med Chem.* 1987; 30:238–239. [PubMed: 3027336]
18. Stevens WC Jr, Jones RM, Subramanian G, Metzger TG, Ferguson DM, Portoghese PS. Potent selective indolomorphinan antagonists of the kappa-opioid receptor. *J Med Chem.* 2000; 43:2759–2769. [PubMed: 10893314]
19. Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant μ [K303E] opioid receptors. *J Med Chem.* 1998; 41:4911–4914. [PubMed: 9836606]
20. Jones RM, Portoghese PS. 5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. *Eur J Pharmacol.* 2000; 396:49–52. [PubMed: 10822054]
21. Thomas JB, Atkinson RN, Rothman RB, Fix SE, Mascarella SW, Vinson NA, Xu H, Dersch CM, Lu Y, Cantrell BE, Zimmerman DM, Carroll FI. Identification of the first *trans*-(3*R*,4*R*)-dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. *J Med Chem.* 2001; 44:2687–2690. [PubMed: 11495579]
22. Patkar KA, Yan X, Murray TF, Aldrich JV. [Nalphanolone-11- β -D-glucopyranoside]-dynorphin A-(1-11)NH₂ cyclized in the “address” domain is a novel kappa-opioid receptor antagonist. *J Med Chem.* 2005; 48:4500–4503. [PubMed: 15999987]
23. Bennett MA, Murray TF, Aldrich JV. Identification of aroclon, a novel acetylated dynorphin A-(1-11) analogue, as a kappa opioid receptor antagonist. *J Med Chem.* 2002; 45:5617–5619. [PubMed: 12477343]
24. Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE, Mascarella SW, Rothman RB, Xu H, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI. Identification of (3*R*)-7-hydroxy-*N*-((1*S*)-1-[[[(3*R*,4*R*)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. *J Med Chem.* 2003; 46:3127–3137. [PubMed: 12825951]
25. Thomas JB, Fix SE, Rothman RB, Mascarella SW, Dersch CM, Cantrell BE, Zimmerman DM, Carroll FI. Importance of phenolic address groups in opioid kappa receptor selective antagonists. *J Med Chem.* 2004; 47:1070–1073. [PubMed: 14761209]

26. Cai TB, Zou Z, Thomas JB, Brieady L, Navarro HA, Carroll FI. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). *J Med Chem.* 2008; 51:1849–1860. [PubMed: 18307295]
27. Thomas JB, Fall MJ, Cooper JB, Rothman RB, Mascarella SW, Xu H, Partilla JS, Dersch CM, McCullough KB, Cantrell BE, Zimmerman DM, Carroll FI. Identification of an opioid κ receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. *J Med Chem.* 1998; 41:5188–5197. [PubMed: 9857089]
28. Liao LA, Zhang F, Yan N, Golen JA, Fox JM. An efficient and general method for resolving cyclopropene carboxylic acids. *Tetrahedron.* 2004; 60:1803–1816.
29. Chatterjee A, Roy D, Chatterjee SK. An Efficient General-Method for the Synthesis of Some Intermediates for Heterocyclic Steroids. *Synthesis-Stuttgart.* 1981:449–451.
30. Hamada Y, Hayashi K, Shioiri T. Efficient Stereoselective Synthesis of Dolastatin-10, an Antineoplastic Peptide from a Sea Hare. *Tetrahedron Lett.* 1991; 32:931–934.
31. Venugopal VK, Rao N, Rahman MF, Bhalerao UT, Thyagarajan G. A Study of Electronic Effects Involving Electron Deficient Nitrogen. 4. Schmidt and Beckmann Rearrangements of Isoquinolinones and Isothiachromanone. *Indian Journal of Chemistry Section B-Organic Chemistry Including Medicinal Chemistry.* 1981; 20:156–157.
32. Mander LN, Sethi SP. Regioselective Synthesis of Beta-Ketoesters from Lithium Enolates and Methyl Cyanoformate. *Tetrahedron Lett.* 1983; 24:5425–5428.
33. West CT, Donnelly SJ, Kooistra DA, Doyle MP. Silane Reductions in Acidic Media .2. Reductions of Aryl Aldehydes and Ketones by Trialkylsilanes in Trifluoroacetic Acid - Selective Method for Converting Carbonyl Group to Methylene. *J Org Chem.* 1973; 38:2675–2681.
34. Ramadas SR, Chaudhuri AP, Suryaprakash GK. Heterocyclic Steroids .5. Studies on Total Synthesis of Racemic 3-Methoxy-7-Oxaestra-1,3,5(10), 8-Tetraen-17(E)-Ol. *Steroids.* 1976; 28:197–209. [PubMed: 973235]
35. Feutrill GI, Mirringt Rn. Demethylation of Aryl Methyl Ethers with Thioethoxide Ion in Dimethyl Formamide. *Tetrahedron Lett.* 1970:1327–1328.
36. Carroll FI, Chaudhari S, Thomas JB, Mascarella SW, Gigstad KM, Deschamps J, Navarro HA. N-Substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists. *J Med Chem.* 2005; 48:8182–8193. [PubMed: 16366600]
37. Metcalf MD, Coop A. Kappa opioid antagonists: past successes and future prospects. *AAPS J.* 2005; 7:E704–E722. [PubMed: 16353947]
38. Aldrich, JV.; Vigil-Cruz, SC. Narcotic Analgesics. In: Abraham, DJ., editor. *Burger's Medicinal Chemistry and Drug Discovery.* 6th. Vol. 6. John Wiley & Sons; New York, NY: 2003. p. 329-481. Chapter 7
39. Schwyzner R. ACTH: A short introductory review. *Ann N Y Acad Sci.* 1977; 297:3–26. [PubMed: 211904]
40. Metzger TG, Paterlini MG, Portoghese PS, Ferguson DM. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. *Neurochem Res.* 1996; 21:1287–1294. [PubMed: 8947918]
41. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine. *Mol Pharmacol.* 1995; 47:1089–1094. [PubMed: 7541509]
42. Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. *J Med Chem.* 2000; 43:1573–1576. [PubMed: 10780914]
43. Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the “address” recognition locus. *J Med Chem.* 2001; 44:857–862. [PubMed: 11300867]
44. Portoghese PS. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. *J Med Chem.* 2001; 44:2259–2269. [PubMed: 11428919]

45. Carroll FI, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS. Pharmacological properties of JD_{Tic}: A novel κ -opioid receptor antagonist. *Eur J Pharmacol.* 2004; 501:111–119. [PubMed: 15464069]

a Abbreviations

GPCRs	G-protein-coupled receptors
cDNAs	complementary deoxyribonucleic acid
SAR	structure activity relationship
[³⁵S]GTPγS	sulfur-35 guanosine-5'- <i>O</i> -(3-thio)triphosphate
DAMGO	[D-Ala ² ,MePhe ⁴ ,Gly-ol ⁵]enkephalin
DPDPE	[D-Pen ² ,D-Pen ⁵]enkephalin
U69,593	(5 α ,7 α ,8 β)-(-)- <i>N</i> -methyl- <i>N</i> -[7-(1-pyrrolidiny)-1-oxaspiro[4,5]dec-8-yl]benzeneacetamide
CHO	Chinese hamster ovary
GDP	guanosine diphosphate
BOP	benzotriazole-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
HBTU	<i>O</i> -(benzotriazol-1-yl)- <i>N,N,N',N'</i> -tetramethyluronium hexafluorophosphate
HMPA	hexamethylphosphoramide
LOA	lithium diisopropylamide
Tic	tetrahydroisoquinolinecarboxylic acid
SAR	structure-activity relationship

Figure 1.

Alignment of a local-energy minimum conformation of **3** (grey) and **2** (green) with heteroatoms indicated by CPK-colored spheres (blue for nitrogen and red for oxygen). Possible shared-pharmacophore regions are labeled "A" for the opioid address region, "M" for the opioid message region and "P" for a polar interaction site adjacent to the protonated nitrogens.

Figure 2.

Comparison of **7a** to **3** on U50,488-induced diuresis in rats. (A) Antagonism of U50,488-induced urine output in various s.c. doses (mg/kg) of **3**. (B) Antagonism of U50,488-induced urine output by various s.c. doses (mg/kg) of **7a**, and compound **3** and **7a** were only administered once at week 0.

Scheme 1a.

^aReagents and conditions: (a) BOP, TEA, THF, 25 °C.

Scheme 2a.

^aReagents and conditions: (a) thionyl chloride, toluene; (b) EtLi, (3aR-*Cis*)-3,3a,8,8a-tetrahydro-2H-indeno[1,2d]oxazol-2-one (**14**); (c) 30% H₂O₂, LiOH, 3:1 THF/H₂O; (d) **12**, BOP, TEA, THF 25 °C; (e) BBr₃, CH₂Cl₂ -78 °C.

Scheme 3a.

^aReagents: (a) CH_3I , LDA, HMPA, THF; (b) Et_3SiH , TFA; (c) KOH, CH_3OH , 0 °C; (d) $(\text{COCl})_2$, CH_2Cl_2 ; (e) **14**, EtLi, THF; (f) LiOH, THF/ H_2O ; (g) **12**, BOP, TEA, THF, 25 °C; (h) BBr_3 , CH_2Cl_2 , -78 °C; (i) MCPBA, CH_2Cl_2 , 0 °C.

Scheme 4a.

^aReagents and conditions: (a) Oxalyl chloride, CH₂Cl₂; (b) SnCl₄, chlorobenzene, 0 °C; (c) NaSEt, DMF, reflux; (d) MOMCl, *i*-Pr₂EtN; (e) methyl cyanofomate, LDA HMPA, THF; (f) TFA, Et₂SiH; (g) LiOH, THF/MeOH/H₂O, (1:1:1) 0 °C; (h) **12**, BOP, TEA, THF, 25 °C; (i) preparative HPLC.

[AcPhe^{1,2,3},Arg⁴,D-Ala⁸]dynorphin A-(1-11) amide (**4**)

[N-benzylTyr¹,cyclo(D-asp⁵,Dap⁸)]Dyn A-(1-11) amide (**5**)

Table 1

Comparison of Inhibition of Agonist-Stimulated [³⁵S]GTPγS Binding in Cloned Human μ, δ, and κ Opioid Receptors for **6**, **7a,b**, **8a,b**, **9a,b**, and **10a,b** to **3** and **1**^{a,b}

compd	μ, DAMGO K _e (nM)	δ, DPDPE K _e (nM)	κ, U69,593 K _e (nM)	μ/κ	δ/κ
1	26.7 ± 7 ^c	29 ± 8 ^c	0.05 ± 0.02 ^c	520	580
3	25.1 ± 3.5 ^c	76.4 ± 2.7 ^c	0.02 ± 0.01 ^c	1255	3830
6	2.53 ± 0.34	219 ± 41	3.93 ± 1.2	0.7	56
7a	6.67 ± 1.2	44.8 ± 7.7	0.18 ± 0.03	37	248
7b	11.2 ± 2.4	205 ± 59	1.37 ± 0.36	8.2	150
8a	7.4 ± 2.6	197 ± 64	0.71 ± 0.16	10	278
8b	5.2 ± 1.6	134 ± 26	5.7 ± 1.6	0.9	24
9a	5.57 ± 1.27	395 ± 122	0.99 ± 0.25	6	399
9b	13.4 ± 2.9	182 ± 48	1.58 ± 0.07	8.5	115
10a	7.9 ± 2.2	208 ± 55	2.7 ± 2.2	2.9	77
10b	1.8 ± 0.3	61 ± 11	0.55 ± 0.12	3.3	111

^a Data represent means ± SE from at least three independent experiments.

^b The average percent stimulation and agonist EC₅₀ values for the μ, κ, and δ [³⁵S]GTPγS binding assays were 200% and 120 nM, 220% and 380 nM, and 50% and 6 nM, respectively. K_e values were calculated from experiments where the antagonist produced at least a 4-fold shift in the agonist ED₅₀.

^c The K_e values for **3** supplied by the NIDA Opioid Treatment Discovery Program (OTDP) were 3.41, 79.3, and 0.01 nM for the μ, δ, and κ receptors, respectively (ref. 24).